title: Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2.
abstract: L-sulforaphane was identified as an anticarcinogen that could produce quinine reductase and a phase II detoxification enzyme. In recent decades, multi-effects of L-sulforaphane may have been investigated, but, to the authors' knowledge, the antiplatelet activation of L-sulforaphane has not been studied yet.In this study, 2 μg/ml of collagen, 50 μg/ml of ADP and 5 μg/ml of thrombin were used for platelet aggregations with or without L-sulforaphane. L-sulforaphane inhibited the platelet aggregation dose-dependently. Among these platelet activators, collagen was most inhibited by L-sulforaphane, which markedly decreased collagen-induced glycoprotein IIb/IIIa activation and thromboxane A2 (TxA2) formation in vitro. L-sulforaphane also reduced the collagen and epinephrine-induced pulmonary embolism, but did not affect prothrombin time (PT) in vivo. This finding demonstrated that L-sulforaphane inhibited the platelet activation through an intrinsic pathway.L-sulforaphane had a beneficial effect on various pathophysiological pathways of the collagen-induced platelet aggregation and thrombus formation as a selective inhibition of cyclooxygenase and glycoprotein IIb/IIIa antagonist. Thus, we recommend L-sulforaphane as a potential antithrombotic drug.
authors: College of Dentistry , Biosafety & Validation Center, Clinical Trial Institute, Dankook University, Cheonan, Chungnam, Republic of Korea.
authors: Chung-Hun
authors: CH
authors: Oh
authors: Jang-In
authors: JI
authors: Shin
authors: Sang Joon
authors: SJ
authors: Mo
authors: Sung-Jo
authors: SJ
authors: Yun
authors: Sung-Hoon
authors: SH
authors: Kim
authors: Yun-Hee
authors: YH
authors: Rhee
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D003094:Collagen / Q000037:antagonists & inhibitors / Q000494:pharmacology; D005260:Female; D005343:Fibrinolytic Agents; D006801:Humans; D017879:Isothiocyanates; D051379:Mice; D008813:Mice, Inbred ICR; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011655:Pulmonary Embolism / Q000188:drug therapy; D013454:Sulfoxides; D013861:Thiocyanates / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors*
chemical_list: D005343:Fibrinolytic Agents; D017879:Isothiocyanates; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013454:Sulfoxides; D013861:Thiocyanates; D013928:Thromboxane A2; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin; C016766:sulforaphane